Skip to main content
SpringerLink
Log in

Botulinum Toxin for Post-stroke Limb Spasticity

  • Chapter
Ischemic Stroke Therapeutics

  • 2167 Accesses

Abstract

Stroke mortality has declined to the fourth leading cause of death with improved risk factors control and better coordinated acute stroke care in the United States (Lackland et al., Stroke 45:315–53, 2014). On the other hand, stroke remains a leading cause of disability. An increasing number of individuals are surviving with a variety of residual physical and cognitive deficits (Clarke et al., Stroke 33:1016–21, 2002; Haacke et al., Stroke 37:193–198, 2006). Of these deficits, post-stroke limb spasticity (PSLS) generally occurs with motor impairment, as a frequent sequela after stroke. Current prevalence estimates of PSLS, from several studies with different sample sizes at varying post-stroke phases, range from 4 to 43 % (Wissel et al., Neurology 80:S13–19, 2013). PSLS is considered a major post-stroke complication with a substantial impact on post-stroke motor recovery and overall quality of life. Spasticity frequently develops weeks or months after strokes and is a major barrier to survivors achieving good motor recovery or independence in the performance of activities of daily living (ADLs). In recent years, several treatments have become available for spasticity treatment, including botulinum toxin.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lackland DT, Roccella EJ, Deutsch AF, Fornage M, George MG, Howard G, Kissela BM, Kittner SJ, Lichtman JH, Lisabeth LD, Schwamm LH, Smith EE, Towfighi A. Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association. Stroke. 2014;45:315–53.

    Article  PubMed  Google Scholar 

  2. Clarke P, Marshall V, Black SE, Colantonio A. Well-being after stroke in Canadian seniors: findings from the Canadian Study of Health and Aging. Stroke. 2002;33:1016–21.

    Article  PubMed  Google Scholar 

  3. Haacke C, Althaus A, Spottke A, Siebert U, Back T, Dodel R. Long-term outcome after stroke: evaluating health-related quality of life using utility measurements. Stroke. 2006;37:193–8.

    Article  PubMed  Google Scholar 

  4. Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013;80:S13–9.

    Article  PubMed  Google Scholar 

  5. Lance J. Spasticity: disorders motor control. In: Feldman RG, Young RP, Koella WP, editors. Symposium synopsis. Miami, FL: Year Book Medical Publishers; 1990.

    Google Scholar 

  6. Burke D. Spasticity as an adaptation to pyramidal tract injury. Adv Neurol. 1988;47:401–23.

    CAS  PubMed  Google Scholar 

  7. Benecke R. The role of the corticospinal tract in spasticity studied by magnetic brain stimulation. In: Thilmann AF, Burke D, Rymer W, editors. Spasticity. Springer Berlin Heidelberg;1993:89–100.

    Google Scholar 

  8. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner. 1964;192:540–2.

    CAS  PubMed  Google Scholar 

  9. Patrick E, Ada L. The Tardieu Scale differentiates contracture from spasticity whereas the Ashworth Scale is confounded by it. Clin Rehabil. 2006;20:173–82.

    Article  PubMed  Google Scholar 

  10. Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, McAfee A, Ruffing K, Thompson B, Williams M, Lee CH, Turkel C. Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil. 2002;83:1349–54.

    Article  PubMed  Google Scholar 

  11. Bakheit AM. The pharmacological management of post-stroke muscle spasticity. Drugs Aging. 2012;29:941–7.

    Article  CAS  PubMed  Google Scholar 

  12. Sahin N, Ugurlu H, Albayrak I. The efficacy of electrical stimulation in reducing the post-stroke spasticity: a randomized controlled study. Disabil Rehabil. 2012;34:151–6.

    Article  PubMed  Google Scholar 

  13. Olvey EL, Armstrong EP, Grizzle AJ. Contemporary pharmacologic treatments for spasticity of the upper limb after stroke: a systematic review. Clin Ther. 2010;32:2282–303.

    Article  CAS  PubMed  Google Scholar 

  14. Simpson DM, Alexander DN, O’Brien CF, Tagliati M, Aswad AS, Leon JM, Gibson J, Mordaunt JM, Monaghan EP. Botulinum toxin type a in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology. 1996;46:1306–10.

    Article  CAS  PubMed  Google Scholar 

  15. Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, Lee CH, Jenkins S, Turkel C. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med. 2002;347:395–400.

    Article  CAS  PubMed  Google Scholar 

  16. Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, Walcott JM, Jenkins SW, Turkel C, Molloy PT. Dose-dependent response to intramuscular botulinum toxin type a for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil. 2004;85:1063–9.

    Article  PubMed  Google Scholar 

  17. Marciniak CM, Harvey RL, Gagnon CM, Duraski SA, Denby FA, McCarty S, Bravi LA, Polo KM, Fierstein KM. Does botulinum toxin type a decrease pain and lessen disability in hemiplegic survivors of stroke with shoulder pain and spasticity?: a randomized, double-blind, placebo-controlled trial. Am J Phys Med Rehabil. 2012;91:1007–19.

    Article  PubMed  Google Scholar 

  18. Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, Benecke R, Collin C, Muller F, Ward CD, Neumann C. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type a (dysport) with placebo in upper limb spasticity after stroke. Stroke. 2000;31:2402–6.

    Article  CAS  PubMed  Google Scholar 

  19. Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type a in upper limb spasticity in patients with stroke. Eur J Neurol. 2001;8:559–65.

    Article  CAS  PubMed  Google Scholar 

  20. McCrory P, Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Sandanam J, Davies L, Munns M, Hughes A. Botulinum toxin A for treatment of upper limb spasticity following stroke: a multi-centre randomized placebo-controlled study of the effects on quality of life and other person-centred outcomes. J Rehabil Med. 2009;41:536–44.

    Article  PubMed  Google Scholar 

  21. Brashear A, McAfee AL, Kuhn ER, Fyffe J. Botulinum toxin type b in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil. 2004;85:705–9.

    Article  PubMed  Google Scholar 

  22. Farina S, Migliorini C, Gandolfi M, Bertolasi L, Casarotto M, Manganotti P, Fiaschi A, Smania N. Combined effects of botulinum toxin and casting treatments on lower limb spasticity after stroke. Funct Neurol. 2008;23:87–91.

    PubMed  Google Scholar 

  23. Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, Group GSKSS. Botulinum toxin type a in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial. J Neurol. 2010;257:1330–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512–5.

    Article  CAS  PubMed  Google Scholar 

  25. Dunne JW, Gracies JM, Hayes M, Zeman B, Singer BJ, Multicentre SG. A prospective, multicentre, randomized, double-blind, placebo-controlled trial of onabotulinumtoxinA to treat plantarflexor/invertor overactivity after stroke. Clin Rehabil. 2012;26:787–97.

    Article  PubMed  Google Scholar 

  26. Fietzek UM, Kossmehl P, Schelosky L, Ebersbach G, Wissel J. Early botulinum toxin treatment for spastic pes equinovarus–a randomized double-blind placebo-controlled study. Eur J Neurol. 2014;21:1089–95.

    Article  CAS  PubMed  Google Scholar 

  27. Naumann M, So Y, Argoff CE, Childers MK, Dykstra DD, Gronseth GS, Jabbari B, Kaufmann HC, Schurch B, Silberstein SD, Simpson DM, Therapeutics, Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70:1707–14.

    Article  CAS  PubMed  Google Scholar 

  28. Sheean G, Lannin NA, Turner-Stokes L, Rawicki B, Snow BJ, Cerebral PI. Botulinum toxin assessment, intervention and after-care for upper limb hypertonicity in adults: international consensus statement. Eur J Neurol. 2010;17 Suppl 2:74–93.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr. Wayne Feng receives grant support from American Heart Association—Scientist Development Grant (14SDG1829003) and from National Institute of Health (Center of Biomedical Research Excellence in Stroke Recovery 1P20 GM109040). He is also a site PI for Adult SPasticity International REgistry on BOTOX® Treatment (ASPIRE).

Author information

Authors and Affiliations

  1. Department of Neurology, Hainan Medical College, 31 Longhua Road, Haikou, Hainan, 570102, China

    Rong Chen M.D., M.S.

  2. Department of Neurology and Neurosurgery, Medical University of South Carolina, 19 Hagood Avenue, HOT-501, Charleston, SC, 29425, USA

    Wuwei Feng M.D., M.S.

Authors
  1. Rong Chen M.D., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wuwei Feng M.D., M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wuwei Feng M.D., M.S. .

Editor information

Editors and Affiliations

  1. Admiral Pihl Professor and Chairman of Neurology, Medical University of South Carolina, Charleston, South Carolina, USA

    Bruce Ovbiagele

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chen, R., Feng, W. (2016). Botulinum Toxin for Post-stroke Limb Spasticity. In: Ovbiagele, B. (eds) Ischemic Stroke Therapeutics. Springer, Cham. https://doi.org/10.1007/978-3-319-17750-2_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-17750-2_19

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-17749-6

  • Online ISBN: 978-3-319-17750-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation